Elevance Health Inc.'s Stock Analysis

Elevance Health Announces Management Changes and Earnings Guidance

Elevance Health has announced key management changes, including Peter D. Haytaian's transition from Executive Vice President and President of Carelon to Special Advisor effective May 4, 2026, due to family commitments. Mark Kaye, the current Chief Financial Officer, will expand his responsibilities to oversee Carelon, while Felicia Norwood will lead the consolidated Health Benefits organization. These changes aim to enhance decision-making and execution across the company’s operations.

The company reaffirmed its earnings guidance for the full year 2026, expecting at least $22.30 per diluted share, which includes approximately $3.20 per diluted share of net unfavorable items. Excluding these items, adjusted earnings are anticipated to be at least $25.50 per diluted share. Elevance Health also confirmed its benefit expense ratio guidance for the year as 90.2%, plus or minus 50 basis points.

Feb 26, 2026 14:59:29

Elevance Health Reports Q4 and Full Year 2025 Results

Elevance Health reported operating revenue of $49.3 billion for the fourth quarter of 2025, marking a 10% increase compared to the same period last year. For the full year 2025, the company achieved operating revenue of $197.6 billion, up 13% year-over-year, driven by higher premium yields and growth in Medicare Advantage membership, despite some attrition in its Medicaid business. The diluted earnings per share (EPS) for Q4 2025 was $2.47, with an adjusted diluted EPS of $3.33, while the full year diluted EPS stood at $25.21, with an adjusted EPS of $30.29. The company also reported a benefit expense ratio of 93.5% for Q4 2025, reflecting increased medical costs, particularly in its Affordable Care Act health plans.

In terms of cash flow, Elevance Health generated $4.3 billion in operating cash flow for 2025 and returned $4.1 billion to shareholders through share repurchases and dividends. The company declared a first quarter 2026 dividend of $1.72 per share, payable on March 25, 2026. Elevance Health's medical membership totaled approximately 45.2 million as of December 31, 2025, reflecting a slight decline due to Medicaid attrition. The company maintained a focus on expense discipline while investing in workforce and technology improvements, and it has a remaining share repurchase authorization of approximately $6.7 billion.

Jan 28, 2026 06:03:02

Elevance Health Appoints Amy Schulman as Independent Director

Elevance Health's Board of Directors has elected Amy W. Schulman as an independent director, effective January 12, 2026. Schulman will also serve on the Audit and Finance Committees. She is recognized for her expertise in healthcare innovation and governance, and has no material interest in any transactions that would require disclosure. Her appointment aligns with the company's strategy to ensure diverse leadership and enhance long-term value for shareholders.

Schulman currently holds the position of Managing Partner at Polaris Partners and has significant experience in the healthcare sector, including previous senior roles at Pfizer Inc. Her background in regulatory strategy and investment is expected to contribute to Elevance Health’s mission of improving health outcomes. The company serves 109 million consumers through a comprehensive range of healthcare solutions.

Dec 10, 2025 16:35:16

Elevance Health Reaffirms Earnings Guidance for 2025

Elevance Health, Inc. plans to engage with investors in the upcoming week, reaffirming its earnings guidance for the full year 2025 at approximately $24.70 per diluted share. This figure includes about $5.30 per diluted share of net unfavorable items. Excluding these items, the company anticipates adjusted earnings to be around $30.00 per diluted share. Additionally, the benefit expense ratio guidance for 2025 is expected to be approximately 90.0%, reflecting the company's assessment of current market conditions and operational performance.

The company's expectations are based on various factors, including cost trends and medical claims payable estimates. However, management cautions that actual results may vary significantly if business conditions or assumptions change. The document also outlines several risks that could impact the company’s performance, such as healthcare cost trends, regulatory changes, and operational challenges, which may influence investor decisions.

Nov 10, 2025 17:03:08

Elevance Health Reports Third Quarter 2025 Financial Results

Elevance Health, Inc. reported operating revenue of $50.1 billion for the third quarter of 2025, marking a 12% increase compared to the same period last year. This growth was attributed to higher premium yields in the Health Benefits segment, acquisitions, and an increase in Medicare Advantage membership, although it faced challenges from ongoing losses in Medicaid membership due to eligibility verifications. The benefit expense ratio rose to 91.3%, and the operating expense ratio improved to 10.5%. Cash flow from operations year-to-date was $4.2 billion, with a notable share repurchase of 2.9 million shares totaling $875 million during the quarter.

The Health Benefits segment generated $42.2 billion in revenue, a 10% increase year-over-year, while the Carelon segment reported $18.3 billion in revenue, up 33% from the previous year. The company declared a quarterly dividend of $1.71 per share, payable on December 19, 2025. Elevance Health serves approximately 109 million consumers and is focused on enhancing affordability and member experience through value-based care partnerships and technology solutions.

Oct 21, 2025 06:01:35

Elevance Health Issues $2.97 Billion in New Notes

Elevance Health, Inc. has completed the sale of $2.97 billion in new notes, including $750 million of 4.000% notes due 2028, $750 million of 4.600% notes due 2032, $1 billion of 5.000% notes due 2036, and $500 million of 5.700% notes due 2055. These notes were issued under an underwriting agreement and have been registered under the Securities Act. The company intends to use the proceeds primarily to repay existing senior notes and for general corporate purposes, including working capital and potential acquisitions.

The notes have various maturity dates ranging from 2028 to 2055, with interest payments scheduled semi-annually. The company has the option to redeem the notes before their maturity dates under specific conditions. Additionally, if a change of control occurs, and the notes are downgraded below investment grade, the company is obligated to offer to purchase the notes at a premium. The issuance of these notes may impact the company's financial leverage and liquidity position, which are important factors for investors.

Sep 15, 2025 16:05:10

Elevance Health Reaffirms Earnings Guidance for 2025

Elevance Health, Inc. plans to engage with investors in the coming weeks, during which company officers will reaffirm the earnings guidance for the full year 2025. The expected earnings are approximately $24.10 per diluted share, which includes about $5.90 per diluted share of net unfavorable items. Excluding these items, the adjusted earnings guidance is approximately $30.00 per diluted share. Additionally, the company expects a benefit expense ratio of around 90.0% for the same period.

The company's guidance reflects current views on market conditions, operational performance, and key business assumptions. However, actual results may differ significantly if business factors or assumptions change. Investors are advised to consider various risks that could impact the company's performance, including healthcare cost trends, regulatory changes, competitive pressures, and potential cybersecurity issues. This information is important for understanding the potential risks and rewards associated with investing in Elevance Health.

Sep 04, 2025 06:02:07

Elevance Health Appoints Steve Collis as New Board Director

Elevance Health has elected Steven H. Collis as an independent director, effective August 1, 2025. He will serve a term that expires at the 2027 annual meeting and will also join the Audit and Finance Committees. Collis has been recognized as an audit committee financial expert and will receive standard compensation for his role as a director, as outlined in the company's existing compensation program for non-employee directors.

Steve Collis brings extensive experience in the healthcare sector, having previously served as the Executive Chairman of Cencora and as its President and CEO for 13 years. His appointment is part of Elevance Health's strategy to enhance governance and align board expertise with the company's growth objectives in a changing healthcare landscape. The board's decision reflects a commitment to evolving its membership to better address stakeholder needs and industry demands.

Jul 28, 2025 16:38:34

Elevance Health Reports Q2 2025 Financial Results and Guidance

Elevance Health, Inc. reported operating revenue of $49.4 billion for the second quarter of 2025, reflecting a 14.3% increase compared to the same quarter in 2024. The rise in revenue was attributed to higher premium yields in the Health Benefits segment, recent acquisitions, and growth in Medicare Advantage membership, though this was partially offset by membership attrition in the Medicaid business. The company reported a diluted earnings per share (EPS) of $7.72, with an adjusted diluted EPS of $8.84. The company has revised its full-year 2025 adjusted diluted EPS guidance to approximately $30.00, amid elevated medical cost trends in ACA and slower rate alignment in Medicaid.

As of June 30, 2025, Elevance Health had operating cash flow of $3.1 billion, with cash and investments at the parent company totaling approximately $2.2 billion. The company repurchased 0.9 million shares for $379 million during the second quarter and declared a quarterly dividend of $1.71 per share, payable on September 25, 2025. The Health Benefits segment generated $41.6 billion in operating revenue, while Carelon's revenue was $18.1 billion, a 36% increase year-over-year. Overall, the company aims for at least 12% average annual growth in adjusted diluted EPS over time, supported by its diversified business segments.

Jul 17, 2025 06:03:40

Company Discloses Risks and Challenges in Financial Performance

The press release outlines various risks and uncertainties that could affect the company's financial performance, including trends in healthcare costs, reduced enrollment, and the impact of regulatory changes. It highlights concerns related to competition, the ability to secure premium rates, and potential cybersecurity incidents as significant challenges the company may face moving forward.

On the positive side, the company emphasizes its commitment to maintaining and improving its quality scores and the importance of its relationships with providers. It also notes the potential for growth through strategic alliances and the ongoing evaluation of its operational capabilities to adapt to industry changes, indicating a focus on long-term sustainability.

Mar 10, 2025 16:17:17